Metlay JP Powers JH Dudley MN Christiansen K Finch RG Antimicrobial Drug Resistance Regulation and Research Emerg Infect Dis 2006122183190 httpsdoiorg103201eid1202050078 ID: 1046069
Download Presentation The PPT/PDF document "Figure 3 Figure 3. Relationship..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Figure 3Figure 3. Relationship between MIC and attainment of the pharmacokinetic/pharmacodynamic (PK/PD) target for effect. Accumulating evidence supports the use of separate PK/PD breakpoints for clinical decision making, distinct from in vitro breakpoints used for epidemiologic surveillance. A breakpoint derived from PK/PD data represents the highest MIC for which the unbound plasma concentrations of the drug (after standard doses) are sufficient to achieve the target PK/PD exposure.Metlay JP, Powers JH, Dudley MN, Christiansen K, Finch RG. Antimicrobial Drug Resistance, Regulation, and Research. Emerg Infect Dis. 2006;12(2):183-190. https://doi.org/10.3201/eid1202.050078